In our study, the percentage of BRAF mutations in each subtype showed that only 8.5% of ALM patients and 4.8% of MCM patients harbored a BRAF mutation, whereas more than 60% of SSM patients carried the mutation. This evidence concerns the gene BRAF and acral lentiginous melanoma.